EGFR

[Biomarker Research] The authors systematically review the recent clinical research of and treatments used for epidermal growth factor receptor ex20ins mutations, summarize the latest data on emerging therapies, and discuss future prospects and treatments.

[Cancer Research] Researchers identified that loss of an epigenetic factor, lysine methyltransferase 5C (KMT5C), drove resistance of NSCLC to multiple EGFR inhibitors, including erlotinib, gefitinib, afatinib, and osimertinib.

[Janssen Pharmaceutical Companies] The Janssen Pharmaceutical Companies of Johnson & Johnson announced that Health Canada has issued a Notice of Compliance with Conditions approving RYBREVANT®, a fully-human, bispecific antibody, for the treatment of adult patients with locally advanced or metastatic NSCLC.

[iScience] Knockdown of betacellulin inhibited the growth of EGFR-mutant human lung adenocarcinoma cells in culture and their tumor-forming ability in mice.

[Cell Death Discovery] Using iTRAQ-based quantitative proteomics analysis, we identified that nicotinamide N-methyltransferase was significantly increased in epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-resistant NSCLC cells.

[Science Signaling] In cultured oral epithelial cells, candidalysin activated the MAPK p38, which resulted in heat shock protein 27 (Hsp27) activation, IL-6 release, and EGFR phosphorylation without affecting the induction of c-Fos.